NeOnc Technologies Holdings, Inc. (NTHI)
| Market Cap | 81.03M -56.3% |
| Revenue (ttm) | 39,990 +100.0% |
| Net Income | -47.20M |
| EPS | -2.14 |
| Shares Out | 24.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 131,607 |
| Open | 3.160 |
| Previous Close | 3.120 |
| Day's Range | 3.101 - 3.380 |
| 52-Week Range | 2.501 - 12.000 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 17.00 (+421.47%) |
| Est. Earnings | Nov 13, 2026 |
About NTHI
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary bra... [Read more]
Financial Performance
In 2025, NTHI's revenue was $39,990, a decrease of -51.82% compared to the previous year's $83,000. Losses were -$62.15 million, 422.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for NTHI stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 421.47% from the latest price.
News
NeOnc's Ambitious Brain Cancer Plans are Setting the Stage
DENVER, Oct. 30, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews.com) — In a market where the latest whizbang trends often dominate investor attention, NeOnc Technologies Holdings (NASDAQ:NTHI) is pursuing ...
NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries
DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) is setting its sights on a substantially larger international clinical effort, outlining pl...
NeOnc Breaks Through Key Levels, as Brain-Cancer Stock's Catalysts Continue
DENVER, Oct. 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) cleared several key resistance levels, on strong trading volume, delivering a potentially impo...
NeOnc Heads to Fox Business as Brain Cancer Milestones Put Its Mission in the Spotlight
NeOnc (NASDAQ: NTHI) is taking its brain cancer story to Fox Business Network when several developments put the clinical-stage biotech in the spotlight
NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy
CALABASAS, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for ce...
NeOnc's Brain Cancer Efforts Bring Hope as FDA Meeting Approaches
Compassionate care for children in Abu Dhabi, a new research MoU and a senior banking appointment add momentum to NeOnc's development story Houston, Texas--(Newsfile Corp. - October 21, 2026) - As NeO...
NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward
DENVER, Oct. 21, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) — “I wish someone had told me about that company.” That is a familiar reaction when a stock attracts attention after investors have spen...
NeOnc Technologies and the Department of Health – Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical Collaboration
Proposed collaboration covers scientific exchange, specialist training and real-world evidence, alongside assessment of clinical trial opportunities and a potential regional presence for NeOnc in Abu ...
Forget the Ugly Sweaters and Ugly Charts, NeOnc is Ready for Catalyst Season
DENVER, Oct. 20, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) -- At an ugly-sweater party, the one with the most flair gets everyone talking. On Wall Street, attention can shift just as quickly when...
NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus
Pediatric Case, Abu Dhabi Expansion and Board Appointment Highlight a Broader Development Strategy Houston, Texas--(Newsfile Corp. - October 16, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is c...
NeOnc's Boldest Test Yet: Child's Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone
DENVER, Oct. 16, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) delivered a deeply human clinical update that brings its investigational brain-cancer tech...
NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi
CALABASAS, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for ce...
UAE Banking Heavyweight Joins NeOnc as Global Brain-Cancer Drug Development Advances
DENVER, Oct. 15, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) – NeOnc Technologies Holdings (NASDAQ: NTHI) made a powerful leadership move at a pivotal moment in its brain-cancer drug development st...
NeOnc CEO Amir F. Heshmatpour to Address Global Life Sciences Investment at Abu Dhabi Future Health Summit 2026
CALABASAS, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies ...
NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development
NeOnc (NASDAQ:NTHI) is strengthening its boardroom, as its clinical-development progress seeks to advance treatments for some of the most difficult cancers
NeOnc Technologies Appoints Ali Alabedin to Its Board of Directors
CALABASAS, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for ce...
NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer
DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com)-- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time? A ser...
NeOnc's FDA Catalyst Run Could Give NTHI a Serious Jolt
DENVER, Oct. 06, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) -- A fall calendar is bringing NeOnc Technologies Holdings' (NASDAQ: NTHI) investigational brain-cancer programs into focus. Anticipatio...
NeOnc Technologies announces brain cancer pipeline advances
NeOnc Technologies (NTHI) is heading toward another potentially important regulatory milestone, with the U.S. Food and Drug Administration scheduled to meet with the company on November 17, 2026, for ...
NeOnc's Powerful Brain Cancer Pipeline Advances
DALLAS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is heading toward another potentially important regulatory milestone, with the U.S. Foo...
Powerful NeOnc Brain Cancer Pipeline Advances
NeOnc (NASDAQ: NTHI) is scheduled to meet with the FDA for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212.
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
CALABASAS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for c...
NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst
DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has picked up fresh Wall Street coverage at a pivotal moment for its experimental brain-c...
NeOnc Technologies initiated with a Buy at Roth Capital
Roth Capital analyst Jonathan Aschoff initiated coverage of NeOnc Technologies (NTHI) with a Buy rating and $20 price target The firm sees the company’s NEO100 and NEO212 launching in 2029…
NeOnc's Delivery may Finally Change the Equation for Brain Cancer's Next Frontier
DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com)– NeOnc Technologies Holdings (NASDAQ: NTHI) is becoming a prominent player, as brain cancer research is entering an increasingly sophisti...